Cisplatin‐resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib

De novo and acquired resistance to platinum therapy such as cisplatin (CDDP) is a clinical challenge in gastric cancer treatment. Aberrant expression and activation of aurora kinase A (AURKA) and eukaryotic translation initiation factor 4E (eIF4E) are detected in several cancer types. Herein, we inv...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lihong, Arras, Janet, Katsha, Ahmed, Hamdan, Saif, Belkhiri, Abbes, Ecsedy, Jeffrey, El‐Rifai, Wael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537695/
https://www.ncbi.nlm.nih.gov/pubmed/28417568
http://dx.doi.org/10.1002/1878-0261.12066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537695/
https://www.ncbi.nlm.nih.gov/pubmed/28417568
http://dx.doi.org/10.1002/1878-0261.12066

Ejemplares similares